Examples of Packages sent

Buy molnunat 200 mg (Molnupiravir) – 40 Tablets

Rated 0 out of 5
(0 customer reviews)


Product Name Molnupiravir (Molunat) 200 mg
Active ingredient (Generic Name) Molnupiravir
Manufacturer NATCO /zydus
Packing 40 Tablest in 1 bott;e
strength 200 mg
Delivery Time 6 to 15 days
SKU Molnupiravir 200

Free shipping order over $150

Each capsule of molnunat 200 mg contains of Molnupiravir and comes 40 capsules per bottle. It is used to treat COVID-19 infected by SAR-CoV-2.

GTIN: Molnupiravir 200 SKU Molnupiravir 200 Category Tags , , ,
Filters Sort results
Reset Apply
Pack size
Add to cart
Molnudac by (Zydus) -40 tablet
Min: 1
Step: 1
Molnunat by (Natco) -40 tablet
Min: 1
Step: 1

Customer reviews

Guaranteed SAFE Checkout

safe checkout

Molnupiravir Information

What is this drug used for?

  • It is used to treat COVID-19 in those infected by SARS-CoV-2.

Adverse Effects


  • Diarrhea (2%)
  • Nausea (1%)
  • Dizziness (1%)


  • Selected Grade 3 and 4 laboratory abnormalities in chemistry (ALT, AST, creatinine, and lipase) and hematology (hemoglobin, platelets, and leukocytes)


  • There are limited clinical data available; serious and unexpected adverse events may occur that have yet to be reported.
  • May cause fetal harm when administered to pregnant females.

Bone and cartilage toxicity

  • Not authorised for use in patients aged <18 years owing to possible effects on bone and cartilage growth
  • Bone and cartilage toxicity was observed in rats after repeated dosing
  • Safety and efficacy have not been established in pediatric patients


  • Not recommended during pregnancy

Dosage Modifications

Renal impairment

  • Mild or moderate (eGFR >30 mL/min): No dosage adjustment necessary
  • Severe (eGFR <30 mL/min), end-stage renal disease, or patients on dialysis: Pharmacokinetics not evaluated; not expected to have a significant effect on NHC (N4-hydroxycytidine) exposure

Hepatic impairment

  • Mild to severe (Child-Pugh Class A to C): No dosage adjustment required
  • Preclinical data indicate that hepatic elimination is not expected to be a major route of NHC elimination

Dosing Considerations

Verify pregnancy status in females of childbearing potential before initiating

Limitations of use

  • Not authorised for use in patients aged <18 years
  • Not authorised for initiation of treatment in patients requiring hospitalization owing to COVID-19
  • Not authorised for use for >5 consecutive days
  • Not authorised for preexposure or postexposure prophylaxis for prevention of COVID-19


Oral Administration

Take orally, with or without food

Missed dose

  • <10 hours: Take missed dose as soon as possible, and resume normal dosing schedule
  • >10 hours: Skip dose, and take the next dose at the regularly scheduled time
  • Do not double dose to make up for missed dose


Store at 20-25ºC (68-77ºF); excursions permitted to 15-30ºC (59-86ºF)


Rated 0 out of 5
0 out of 5 stars (based on 0 reviews)
Very good0%


There are no reviews yet. Be the first one to write one.